Jan-Michael Werner1, Saskia Kuhl1, Pantelis Stavrinou1, Gabriele Röhn1, Boris Krischek1, Tobias Blau2, Roland Goldbrunner1, Marco Timmer3. 1. Department of General Neurosurgery, Center for Neurosurgery, University Hospital Cologne, Cologne, Germany. 2. Institute for Neuropathology, Center for Neurosurgery, University Hospital Cologne, Cologne, Germany. 3. Department of General Neurosurgery, Center for Neurosurgery, University Hospital Cologne, Cologne, Germany marco.timmer@uk-koeln.de.
Abstract
BACKGROUND/AIM: The tumor necrosis factor FAS is overexpressed in high-grade gliomas (HGG). Only little is known about FAS or FAS ligand (FAS-L) in low-grade gliomas (LGG). We explored FAS/FAS-L expression in LGG, focusing on differences in primary and relapsed LGG and on its prognostic value. PATIENTS AND METHODS: A total of 133 glioma samples (73 LGG, 60 HGG) were collected. The LGG samples included 15 matched pairs of primary and relapsed tumors. RT-PCR was performed to measure FAS/FAS-L expression, using subunit A, flavoprotein variant (SDHA) as housekeeper. Clinical data included progression free- (PFS) and overall survival (OS). RESULTS: LGG showed significantly lower FAS but higher FAS-L expression than HGG. The FAS-L expression was higher in primary compared to relapsed LGG and had a positive prognostic value concerning PFS (median 45.20 vs. 31.37 months). CONCLUSION: FAS-L could act as a prognostic marker and potential target in primary LGG. Copyright
BACKGROUND/AIM: The tumor necrosis factor FAS is overexpressed in high-grade gliomas (HGG). Only little is known about FAS or FAS ligand (FAS-L) in low-grade gliomas (LGG). We explored FAS/FAS-L expression in LGG, focusing on differences in primary and relapsed LGG and on its prognostic value. PATIENTS AND METHODS: A total of 133 glioma samples (73 LGG, 60 HGG) were collected. The LGG samples included 15 matched pairs of primary and relapsed tumors. RT-PCR was performed to measure FAS/FAS-L expression, using subunit A, flavoprotein variant (SDHA) as housekeeper. Clinical data included progression free- (PFS) and overall survival (OS). RESULTS: LGG showed significantly lower FAS but higher FAS-L expression than HGG. The FAS-L expression was higher in primary compared to relapsed LGG and had a positive prognostic value concerning PFS (median 45.20 vs. 31.37 months). CONCLUSION:FAS-L could act as a prognostic marker and potential target in primary LGG. Copyright
Authors: Bodo Haas; Veronika Klinger; Christina Keksel; Verena Bonigut; Daniela Kiefer; Julia Caspers; Julia Walther; Maria Wos-Maganga; Sandra Weickhardt; Gabriele Röhn; Marco Timmer; Roland Frötschl; Niels Eckstein Journal: Cancer Cell Int Date: 2018-05-04 Impact factor: 5.722